Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Francesco Caso, Luisa Costa, Paola Triggianese, Francesco Maione, Nicoletta Bertolini, Maria Vastarella, Maria Sole Chimenti & Marco Tasso. (2023) Recent developments for new investigational JAK inhibitors in psoriatic arthritis. Expert Opinion on Investigational Drugs 32:5, pages 361-371.
Read now
Read now
Laura Calabrese, Andrea Chiricozzi, Clara De Simone, Barbara Fossati, Alessandra D’Amore & Ketty Peris. (2022) Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis. Expert Opinion on Drug Metabolism & Toxicology 18:5, pages 347-355.
Read now
Read now
Maria Sole Chimenti, Paola Triggianese, Erica De Martino, Paola Conigliaro, Giulia Lavinia Fonti, Flavia Sunzini, Francesco Caso, Carlo Perricone, Luisa Costa & Roberto Perricone. (2019) An update on pathogenesis of psoriatic arthritis and potential therapeutic targets. Expert Review of Clinical Immunology 15:8, pages 823-836.
Read now
Read now
V Di Lernia & F Bardazzi. (2016) Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis. Drug Design, Development and Therapy 10, pages 533-539.
Read now
Read now
Andrea Chiricozzi, Rosita Saraceno, Lucia Novelli, Monika Fida, Francesco Caso, Raffaele Scarpa, Luisa Costa, Roberto Perricone, Marco Romanelli, Sergio Chimenti & Maria Sole Chimenti. (2016) Small molecules and antibodies for the treatment of psoriasis: a patent review (2010–2015). Expert Opinion on Therapeutic Patents 26:7, pages 757-766.
Read now
Read now
Abraham M. Korman, Dane Hill, Ali Alikhan & Steven R. Feldman. (2016) Oral tofacitinib for the treatment of adults with moderate to severe chronic plaque psoriasis. Expert Review of Clinical Pharmacology 9:4, pages 525-539.
Read now
Read now
Articles from other publishers (22)
Michele Maria Luchetti Gentiloni, Valentino Paci, Antonio Carletto, Alen Zabotti, Roberta Ramonda, Maria Sole Chimenti, Lorenzo Dagna, Nicoletta Luciano, Anna Piccinelli, Ivan Giovannini, Giovanni Striani, Nicola Boffini, Gilda Sandri, Niccolò Possemato, Ilenia Pantano, Devis Benfaremo, Carlo Salvarani, Francesco Ciccia, Carlo Selmi & Gianluca Moroncini. (2023) Upadacitinib effectiveness and factors associated with minimal disease activity achievement in patients with psoriatic arthritis: preliminary data of a real-life multicenter study. Arthritis Research & Therapy 25:1.
Crossref
Crossref
Husna Kadagothy, Shweta Nene, Etikala Amulya, Ganesh Vambhurkar, A.N. Rajalakshmi, Dharmendra Kumar Khatri, Shashi Bala Singh & Saurabh Srivastava. (2023) Perspective insights of small molecules, phytoconstituents and biologics in the management of psoriasis: A focus on targeting major inflammatory cytokine pathways. European Journal of Pharmacology 947, pages 175668.
Crossref
Crossref
Samantha Sarabia, Brandan Ranjith, Sahil Koppikar & Don Thiwanka Wijeratne. (2022) Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis: a systematic review and meta-analysis. BMC Rheumatology 6:1.
Crossref
Crossref
Nilgün Şentürk. (2022) Tofacitinib. TURKDERM, pages 67-69.
Crossref
Crossref
Mohammed Al Abadie, Zinah Sharara, Patrick A Ball & Hana Morrissey. (2022) A Literature Review of the Janus Kinase Inhibitors Used in the Treatment of Auto-Immune Dermatological Conditions. Archives Of Pharmacy Practice 13:2, pages 37-42.
Crossref
Crossref
Weiwei Guo, Fengying Xu, Zhuochen Zhuang, Zhe Liu, Jiming Xie & Liping Bai. (2021) Ebosin Ameliorates Psoriasis-Like Inflammation of Mice via miR-155 Targeting tnfaip3 on IL-17 Pathway. Frontiers in Immunology 12.
Crossref
Crossref
Maria Sole Chimenti, Paola Conigliaro, Livia Biancone & Roberto Perricone. (2021) Update on the therapeutic management of patients with either psoriatic arthritis or ulcerative colitis: focus on the JAK inhibitor tofacitinib. Therapeutic Advances in Musculoskeletal Disease 13, pages 1759720X2097777.
Crossref
Crossref
Sara Mohamed Awad, Yasmin Mostafa Tawfik, Mohamed Ahmed El‐Mokhtar, Amira F. El‐Gazzar & Amira Ali Abdel Motaleb. (2020) Activation of Janus kinase signaling pathway in acne lesions. Dermatologic Therapy 34:1.
Crossref
Crossref
Harsha Jain, Aditi Rajan Bhat, Harshita Dalvi, Chandraiah Godugu, Shashi Bala Singh & Saurabh Srivastava. (2021) Repurposing approved therapeutics for new indication: Addressing unmet needs in psoriasis treatment. Current Research in Pharmacology and Drug Discovery 2, pages 100041.
Crossref
Crossref
Qichao Bao, Liangying Zhang, Nan Wang, Brian Gabet, Weikang Yang, Xingyang Gao, Qidong You & Zhengyu Jiang. (2020) Hydrogen Peroxide Inducible JAK3 Covalent Inhibitor: Prodrug for the Treatment of RA with Enhanced Safety Profile. ACS Medicinal Chemistry Letters 11:11, pages 2182-2189.
Crossref
Crossref
Marco Pellicciaro, Alessandra Vittoria Granai, Gloria Marchese, Marco Materazzo, Maria Cotesta, Francesca Santori, Erica Giacobbi, Francesca Servadei, Sandro Grelli, Tommaso Perretta, Rosaria Meucci, Chiara Adriana Pistolese & Gianluca Vanni. (2020) Breast cancer patients with hormone neoadjuvant bridging therapy due to asymptomatic Corona virus infection. Case report, clinical and histopathologic findings. International Journal of Surgery Case Reports 76, pages 377-380.
Crossref
Crossref
Massimo Gadina, Catrina Johnson, Daniella Schwartz, Michael Bonelli, Sarfaraz Hasni, Yuka Kanno, Paul Changelian, Arian Laurence & John J O’Shea. (2018) Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs. Journal of Leukocyte Biology 104:3, pages 499-514.
Crossref
Crossref
Alexandra Azevedo & Tiago Torres. (2017) Tofacitinib: A New Oral Therapy for Psoriasis. Clinical Drug Investigation 38:2, pages 101-112.
Crossref
Crossref
Andrew Kim & Bruce Strober. 2018. Biologic and Systemic Agents in Dermatology. Biologic and Systemic Agents in Dermatology
187
198
.
Daniella M. Schwartz, Yuka Kanno, Alejandro Villarino, Michael Ward, Massimo Gadina & John J. O'Shea. (2017) JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nature Reviews Drug Discovery 16:12, pages 843-862.
Crossref
Crossref
Jennifer L. Seyffert & Owen N. Kramer. (2017) Review of the role of Janus kinase inhibitors in dermatology. Journal of the Egyptian Womenʼs Dermatologic Society 14:2, pages 73-75.
Crossref
Crossref
Brooke I. Polk & Lanny J. Rosenwasser. (2017) Biological Therapies of Immunologic Diseases. Immunology and Allergy Clinics of North America 37:2, pages 247-259.
Crossref
Crossref
Ruben Vardanyan. 2017. Piperidine-Based Drug Discovery. Piperidine-Based Drug Discovery
127
146
.
Kiyoshi Hirahara, Daniella Schwartz, Massimo Gadina, Yuka Kanno & John J O'Shea. (2016) Targeting cytokine signaling in autoimmunity: back to the future and beyond. Current Opinion in Immunology 43, pages 89-97.
Crossref
Crossref
Amos Gilhar, Adam G. Schrum, Amos Etzioni, Herman Waldmann & Ralf Paus. (2016) Alopecia areata: Animal models illuminate autoimmune pathogenesis and novel immunotherapeutic strategies. Autoimmunity Reviews 15:7, pages 726-735.
Crossref
Crossref
Shrikant R. Mulay, Andreas Linkermann & Hans-Joachim Anders. (2016) Necroinflammation in Kidney Disease. Journal of the American Society of Nephrology 27:1, pages 27-39.
Crossref
Crossref
Daniella M. Schwartz, Michael Bonelli, Massimo Gadina & John J. O'Shea. (2015) Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nature Reviews Rheumatology 12:1, pages 25-36.
Crossref
Crossref